Cargando…

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

The tumour suppressor p53 is the most frequently mutated gene in human cancer. Reactivation of mutant p53 by small molecules is an exciting potential cancer therapy. Although several compounds restore wild-type function to mutant p53, their binding sites and mechanisms of action are elusive. Here co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wassman, Christopher D., Baronio, Roberta, Demir, Özlem, Wallentine, Brad D., Chen, Chiung-Kuang, Hall, Linda V., Salehi, Faezeh, Lin, Da-Wei, Chung, Benjamin P., Wesley Hatfield, G., Richard Chamberlin, A., Luecke, Hartmut, Lathrop, Richard H., Kaiser, Peter, Amaro, Rommie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562459/
https://www.ncbi.nlm.nih.gov/pubmed/23360998
http://dx.doi.org/10.1038/ncomms2361
Descripción
Sumario:The tumour suppressor p53 is the most frequently mutated gene in human cancer. Reactivation of mutant p53 by small molecules is an exciting potential cancer therapy. Although several compounds restore wild-type function to mutant p53, their binding sites and mechanisms of action are elusive. Here computational methods identify a transiently open binding pocket between loop L1 and sheet S3 of the p53 core domain. Mutation of residue Cys124, located at the centre of the pocket, abolishes p53 reactivation of mutant R175H by PRIMA-1, a known reactivation compound. Ensemble-based virtual screening against this newly revealed pocket selects stictic acid as a potential p53 reactivation compound. In human osteosarcoma cells, stictic acid exhibits dose-dependent reactivation of p21 expression for mutant R175H more strongly than does PRIMA-1. These results indicate the L1/S3 pocket as a target for pharmaceutical reactivation of p53 mutants.